By Christina Jewett
Photos December 3, 2019
Lorraine
Bonner felt as though she was the only one. The surgical staples used to seal
her colon after surgery had leaked, she has alleged in a lawsuit, spurring
additional surgeries and a long, difficult recovery.
And
then, just over a year after the ordeal, she read a Kaiser Health News investigation
that described worse cases. KHN revealed that the Food and Drug Administration
had allowed stapler maker Covidien to quietly file tens of thousands of reports
of stapler malfunctions into a then-hidden database.
Alarmed
that others had been harmed and reports had been hidden, Bonner, a retired
Oakland, Calif., doctor, decided to go forward with a lawsuit against the
stapler maker.
“If the
information had been out there, then maybe Covidien would have changed the
design of the staplers and made them safer,” she said, “and that would have
obviated the problem in the first place.”
Bonner’s
lawsuit is one example of how a vast cache of records that were released this
summer are taking on a life of their own.
For
almost 20 years, malfunctions and injuries linked to 108 medical devices,
including dental implants and pacemaker leads, were funneled into an FDA
database that few patients, doctors or even FDA officials knew existed.
In
2016, for example, Covidien reported 84 injuries or malfunctions in the public
database known as MAUDE, while nearly 10,000 incidents flowed into the hidden
database, KHN reported in March. A few MAUDE reports mentioned the existence of
an “alternative summary reporting” program, but until this summer, the FDA made
that internal data available only through the Freedom of Information process,
which can take up to two years.
KHN’s
investigation prompted then-FDA commissioner Scott Gottlieb to pledge in a
tweet to open the hidden data to the public. The agency released all 5.7
million records in June.
Since
then, researchers, lawyers and the FDA’s own officials have taken a closer look
at the data to learn more about which devices malfunctioned, and how often.
Libbe
Englander, the founder and CEO of Pharm3r, a medical data consulting firm,
discovered that the devices in the hidden database were much riskier than other
devices tracked by the FDA.
Her
firm concluded that the hidden reports were “more
likely to be associated with life-threatening devices and to contain
potentially serious problems.”
For
example, just 10% of the devices tracked in the MAUDE database are implanted in
the body. But 44% of those in the hidden data are lodged in a patient’s body,
including pacemakers and heart valves.
The
Pharm3r report also found that the devices in the hidden data were more likely
to be subject to a Class 1 recall, initiated when a device problem could cause
serious injury or death. The report also underscored how vast the now-open data
is ― accounting for about 40% of the total device-problem reports lodged with
the FDA over the past two decades.
The
once-hidden reports also figured into the ECRI Institute’s annual list of
health technology hazards, a list circulated to hospitals and health systems.
ECRI
found that this year’s No. 1 hazard was misuse of the surgical stapler ― which
has been linked to 412 deaths, more than 11,000 serious injuries and nearly
100,000 malfunctions since 2011, according to the FDA.
“Most
of these [stapler] reports had not previously been accessible to the public,”
the ECRI report notes. ECRI
has advised doctors to have a backup plan in place in case a stapler
malfunctions during surgery.
“If a
hazard is getting a lot of attention, hospitals want to have a plan to address
that,” said Rob Schluth, a senior project officer with the institute.
For
Bonner, the problems with a surgical stapler became apparent just over a week
after she had colon surgery in November 2017. Retired from a career as a
hospital physician, she knew the steps to take toward recovery. But she felt
nauseated all the time and could barely hold down water.
“I was
trying to get up and walk,” she said. “I was doing everything, but I just got
worse and worse.”
Doctors
went in for a second surgery on Dec. 6 and found infected pus filling her
abdomen. They routed her colon’s contents to be collected outside her body. It
took additional surgeries to restore her colon function and address hernias
caused by the procedures.
Bonner’s
lawsuit alleges that a Covidien stapler caused her bowel leak and that the
company, by not reporting malfunctions to the public database for years, “have
hidden the true risks of using the device from surgeons and patients.”
In
court records filed in the ongoing case, Covidien denied all of Bonner’s claims
but did say that the FDA invited the company in 2001 to submit stapler
malfunctions with quarterly “alternative summary” reports.
Medtronic
spokesman John Jordan said the company does not have a comment on the pending
legal case.
Other
devices are under scrutiny. The once-hidden data showed more than 2
million problems with dental implants.
During
an October FDA webinar on dental devices, an FDA official
said her office was “taking a deeper dive and trying to identify lessons
learned” from dental implant incidents.
Dr.
Malvina Eydelman, of the Division of Dental Devices in the agency’s device
branch, acknowledged that the number of events was “very high” and said her
team was trying to develop a plan to share information with the public.
Also
under scrutiny are the textured breast implants made by Allergan. The company’s
Biocell implants, recalled in July, have been linked to 12 deaths
and 481 of the 573 worldwide cases of “breast implant-associated” lymphoma,
according to the FDA. Breast implant injuries and malfunctions accounted for
nearly half a million reports in the hidden database, including implants that
leaked, deflated or migrated.
Patients
in Missouri, California, New York and Illinois have filed federal class action
lawsuits against Allergan in recent weeks, each decrying the company’s heavy
use of the “alternative summary reporting” program to file injury reports ―
which were analyzed by the International Consortium of Investigative
Journalists.
A class
action case filed in Florida notes FDA rules say that alternative summary
reports cannot include severe or unexpected events, “yet it is believed that
these incidents were kept hidden in ASRs,” including at least one lymphoma
case.
An
ongoing federal securities lawsuit also alleges that Allergan used
“inappropriately nonpublic” alternative summary reports, disregarding the “risk
that some [lymphoma] cases would go undetected by the FDA.”
Allergan
has not yet responded to the class action cases or to calls for comment. It
denied the “threadbare” allegation in the securities lawsuit, citing the KHN
article, which “makes clear that the filing of ASRs was permissible and even
encouraged by the FDA to reduce ‘redundant paperwork.’”
While
the FDA has ended the alternative summary reporting program, it opened the door
for makers of more than 5,000 device types to file quarterly summaries of reported
malfunctions. In each case, the device maker must file a public report to the
MAUDE database noting how many reports were filed directly with the agency.
An FDA
spokeswoman said the agency has stopped accepting summary reports of injuries
cited in pelvic mesh lawsuits. The agency does continue to accept hundreds of
death report summaries under a special exemption for devices tracked in a
“registry” held by a specialty medical society.
“We are
in the process of reviewing the effects of these changes and will continue
working to improve the usability and transparency of information in the MAUDE
database — whether that information was submitted as a summary or individual
report,” FDA spokeswoman Stephanie Caccomo said in an email.
The
release has not been as informative as Madris Tomes had hoped, she said, given
that the FDA did not disclose data on how the devices harmed patients. Tomes is
a former FDA manager who runs the company Device Events, which analyzes FDA
data.
For
instance, she said a breast implant injury report might say there was a
“biocompatibility” problem, but it’s unclear what happened to the patient.
“Did it
result in lymphoma or the patient needing a device replacement?” asked Tomes.
“Without that outcome, we’re still a little bit in the dark on what this data
means.”
Christina
Jewett: ChristinaJ@kff.org,
@by_cjewett
Heidi
de Marco: heidid@kff.org,
@Heidi_deMarco
No comments:
Post a Comment